³X«È Åwªï±z!   ·|­ûµn¤J


 ¦^¥D­¶  ¡÷    Âå¾Ç±¡³ø  ¡÷  ¥»½g¥DÃD¡G¤ßŦ¦åºÞ¶îÃĤä¬[¤j­²·s¡I¥@¬É­º³Ð-¥i§l¦¬©Ê³æ­±¶îÃĤßŦ¦åºÞ¤ä¬[



 
¡i¤W¤@½g¡j[ FUN´»°²·L¾ã«¬¡@·Rª±¬ü¶E©Ò°|ªø ] ¡i¤U¤@½g¡j[ ¨°¸a®É©|¶E©Ò°|ªø¼B·NÁ{Âå®vªí¥Ü¡A ]

    [·s»D]    ¤ßŦ¦åºÞ¶îÃĤä¬[¤j­²·s¡I¥@¬É­º³Ð-¥i§l¦¬©Ê³æ­±¶îÃĤßŦ¦åºÞ¤ä¬[

    marcopolo168   µoªí©ó 2010/9/29 11:32:16



¦æ¬F°|½Ã¥Í¸p»{ÃÒ³q¹L «a¤ß¯fªvÀø¦³§ó¨Î¿ï¾Ü ®Ú¾Ú½Ã¥Í¸p²Î­p¡A2009¦~¡A°ê¤H¨C¤Ñ¬ù¦³41¤H¦º©ó¤ßŦ¯f¡A¦b¤Q¤j¦º¦]±Æ¦W°ª©~²Ä¤G¦ì¡C°ê¤H¤]¤w¼sªxª¾¹D­Y¦³¤ßŦ¯Ê®ñ²{¶H¥[¤W«aª¬°Ê¯ß¯U¯¶µ{«×¹F¨ì¦åºÞª½®|70%¥H¤WªÌÀ³±µ¨üªvÀø¡C³q±`±Ä¨ú®ð²yÂX±i³N©Î¦åºÞ¤ä¬[¸m©ñ³N¡A¥i¥H¦³®ÄªºªvÀø»PµÎ½w¦]«aª¬°Ê¯ß¯U¯¶©Ò¤Þ°_¤§¤£¾A¯gª¬¡C¤×¨ä¬O¸m©ñ¦åºÞ¤ä¬[«á¡A§ó¥i¥H¤j´T­°§C¦åºÞ­ì¯U¯¶³¡¦ì¦A¯U¯¶ªº¾÷²v¡A¯S§O¬O¶îÃĦåºÞ¤ä¬[ªº¤@¦~¤º¥­§¡¦A¯U¯¶²v¥i¤p©ó10%(¶Ç²Î«D¶îÃĦåºÞ¤ä¬[¤@¦~¤º¥­§¡¦A¯U¯¶²v¬ù30%)¡C¦ý¬O¤ßŦ¯f±w¸Ë¸m¦åºÞ¤ä¬[«á¡A¬O§_´N¥Nªí§¹¥þ¨S¦³¦MÀI©O¡Hªñ¦~¨ÓªºÂå¾Ç¬ã¨s²Î­pµo²{¡G¦åºÞ¤ä¬[¸m©ñ«á¨â¦~¤º¤´¦³¬ù2- 3%ªº¯f±w²£¥Í¦]¦åºÞ¤ä¬[¦Ó§Î¦¨¤§«æ©Ê¦å®ê¡A¦Ó¶îÃĦåºÞ¤ä¬[¬Æ¦Ü¤ñ¶Ç²Î«D¶îÃĦåºÞ¤ä¬[µo¥Í²v§ó°ª¡C¬ÛÃöÂå¾Ç¬ã¨s¤]µo²{³o¨Ç²{¶H»P¸Ë¸m¶îÃĦåºÞ¤ä¬[«á©Ò¤Þµoªº±ß´Á¶îÃĦåºÞ¤ä¬[¤º§Î¦¨¦å®ê¦³Ãö¡C¦]¦¹¶îÃĦåºÞ¤ä¬[©ñ¸m¦b¤HÅ餺¡AÁÙ¬O¦³·¥§Cªº¥i¯à©Êµo¥Í¦åºÞ¤ä¬[¤º¦å®êªº­·ÀI¡C ¨º»ò¦³¤°»ò¤è¦¡¡A¤£¦ý¥i¥H¾Ö¦³¶îÃĤä¬[ªºÀuÂI¡A¦P®É¤]¥i¥H§ó¥[­°§C¥i¯àªº±ß´Á¤ä¬[¤º¦å®ê§Î¦¨­·ÀI©O¡H ¦æ¬F°|½Ã¥Í¸p¤µ¦~8¤ë®Ö­ã¤F¥@¬É­º³Ð¡y¥i§l¦¬³æ­±¶îÃĤßŦ¦åºÞ¤ä¬[¡z¦b¥xÆWªº¨Ï¥Î³\¥i¡C¦¹Á|±N ¬°©Ò¦³ªº«a¤ß¯f±wªÌ±a¨Ó§ó¦w¥þ¤Î§ó¥i¾aªºÂåÀø¿ï¾Ü¡C³oºØ·s«¬ªº¥i§l¦¬³æ­±¶îÃĤßŦ¦åºÞ¤ä¬[¾Ö¦³ ¶Ç²Î¶îÃĦåºÞ¤ä¬[ªº¦³®Ä©Ê¥H¤Î¶Ç²Î«D¶îÃĦåºÞ¤ä¬[ªº¦w¥þ©Ê¨âºØÀuÂI©ó¤@¨­¡A¨ä¥\®Ä¤w¦b³\¦hÁ{§É¬ã¨s¤¤±o¨ìÃÒ¹ê¡A¨ä¤¤¥]¬A°lÂܪø¹F¤T¦~ªºLEADERSÁ{§É¬ã¨s¡C ®Ú¾Ú¤W¶g¡]9¤ë21-25¤é¡^¦b¬ü°êµØ²±¹y©ÒÁ|¦æªº²Ä22©¡¡y¸g¾ÉºÞªvÀø¤ßŦ¦åºÞ¾Ç³N¬ã°Q·|¦~·|¡z(TCT)(Transcatheter Cardiovascular Therapeutics-the 22nd Annual Scientific Symposium )©ÒµoªíªºLEADERSÁ{§É¬ã¨s³ø§i-°lÂܲĤT¦~ªº¸ê®Æ¤ÀªRµ²ªGÅã¥Ü¡A§ó¥[ÃÒ¹ê¤F¡y¥i§l¦¬³æ­±¶îÃĤßŦ¦åºÞ¤ä¬[¡z²`¨ã¹ê»ÚÁ{§É¨Ï¥Î·N¸q¡C ³Ì·sªºLEADERSÁ{§É¬ã¨s³ø§i°lÂܲĤT¦~ªº¸ê®Æ¤ÀªRµ²ªGÅã¥Ü¡A»P¦èù§Q²ö¥q¡]Sirolimus¡^¶Ç²Î¤W ¤@¥NÃĪ«¶î¼h¤ä¬[ÁHºÖ¶îÃĦåºÞ¤ä¬[¬Û¤ñ¡A¡y¥i§l¦¬³æ­±¶îÃĤßŦ¦åºÞ¤ä¬[¡zªº¦w¥þ©Ê§ó¨Î¡CLEADERSÁ{§É¬ã¨s³ø§i¬O²Ä¤@­ÓÀH¾÷ª½±µ¤ñ¸û³o¨âºØÃĪ«¶î¼h¦åºÞ¤ä¬[ªº¬ã¨s³ø§i¡A¨ä¯SÂI¬O¦bÆ[¹î©ó¯u¹ê¥@¬É¤¤©Ò¦³¶îÃĦåºÞ¤ä¬[¤§ªvÀø®ÄªG¡A¨ä¯u¥¿¤Ï¬M¤F¶îÃĦåºÞ¤ä¬[¤§Á{§ÉªvÀø®ÄªG¡C ¬ã¨sµ²ªGÅã¥Ü¡AÁöµM³o¨âºØ¶îÃĦåºÞ¤ä¬[ªº¾ãÅéÀø®Ä¬Û¦ü¡A¦ý¬O¦b¡y¥i§l¦¬³æ­±¶îÃĤßŦ¦åºÞ¤ä¬[¡z¤Þµoªº( MACE, Majority Adverse Cardiac Event )¥]¬A¡G¤ß¦]©Ê¦º¤`¡B¤ß¦Ù±ð¶ë¥H¤Î¦åºÞ¦Aªý¶ë¡A¤ñ¶Ç²Î¤W¤@¥NÃĪ«¶î¼h¦åºÞ¤ä¬[¬°¤Ö¡C¦b¬ã¨sªº²Ä36­Ó¤ë¡]¯f±w¸Ë¸m¶îÃĤä¬[ªº²Ä¤T¦~¡^¡A¥i§l¦¬³æ­±¶îÃĤßŦ¤ä¬[¤Þµoªº¥D­n¤ßŦ¤£¨}¨Æ¥ó¬°15.7%¡A¶Ç²ÎÃĪ«¶î¼h¤ä¬[¬°19.0%¡]P­È=0.09¡^¡C¦b°ª­·ÀI²Õ¡]STEMI¡A¤ß¹q¹ÏSTªi¬q¤É°ª«¬¤ß¦Ù±ð¶ë¡^±wªÌ¤¤¡A¥i§l¦¬³æ­±¶îÃĤßŦ¤ä¬[¤Þµoªº¥D­n¤ßŦ¤£¨}¨Æ¥ó©úÅã¤Ö©ó¶Ç²ÎÃĪ«¶îÃĦåºÞ¤ä¬[¡]«eªÌ9.6% ¡A«áªÌ20.7%¡AP­È=0.01¡^¡C¦b¬ã¨s¤¤¡AÂå¥Í«ØÄ³±wªÌ³sÄò¤@¦~ªA¥Î§t¨âºØ¥H¤W§Ü¦å¤pªOÃĪ«ªvÀø (DAPT)¡A¥H¨¾¤î¦å®êªº§Î¦¨¡C¦b´Ó¤J¥i§l¦¬³æ­±¶îÃĤßŦ¤ä¬[±wªÌ¤¤¡A¦³68%ªº±wªÌ¦b¤â³N«á¤@¦~°±¥Î§Ü¦å¤pªOÃĪ«¡A¨â¦~«á°±¥ÎªÌ¹F92%¡C¦Ó¦b°±¤î¨Ï¥Î§Ü¦å¤pªOÃĪ«ªvÀø¤T¦~«á¡A³£¨S¦³µo²{¨ì±ß´Áªº¦åºÞ¤ä¬[¤º¦å®ê(Very Late Stent Thrombosis )ªº§Î¦¨¡C¡]µù¡GBiolimus A9ÃĪ«ÄÝ©ó¹p©¬Åð¯ÀÃþÃĪ«¡^¡C ¦Û2008¦~°_¡A·s¤@¥N¥i§l¦¬³æ­±¶îÃĤßŦ¦åºÞ¤ä¬[§Y¤wÀò±o¼Ú¬wCE¦w¥þ¼Ð³¹§å­ã¨Ï¥Î¡C¨ä¿W¯SªºÃĪ«¶î¼h¥i¦b¦åºÞ¤ä¬[¸m©ñ«á6¦Ü9­Ó¤ë³Q¤HÅé§l¦¬¡A³o´N¸Ñ¨M¤F²{¦³ªº¶Ç²ÎÃĪ«¶î¼h¦åºÞ¤ä¬[©Ò¥i¯à¤Þ°_ªº¤ä¬[¤º¦å®ê§Î¦¨ªº°ÝÃD¡C³oºØ¦åºÞ¤ä¬[©Ò¥ÎªºÃĪ«Biolimus A9 ¥u³Q¶î¦b¦åºÞ¤ä¬[»P¦åºÞ¾À±µÄ²­±¦P¤@Ãä¡A¯à§ó¦³®Ä¦a±NÃĪ«ÄÀ©ñ¨ì¦åºÞ¾À¨Ã´î¤ÖÃĪ«»P¦å²Gªº¾ãÅé©Ê±µÄ²¡C³Ìªñ¡A·s¤@¥N¥i§l¦¬³æ­±¶îÃĤßŦ¦åºÞ¤ä¬[§óÀò­ã¨Ï¥Î©ó§ó¦hÃþ«¬ªº¯f¤H¡A¥]¬A¤ß¹q¹ÏSTªi¬q¤É°ª«¬¤ß¦Ù±ð¶ë¡]STEMI¡^¡A«æ©Ê«aª¬°Ê¯ßºî¦X¯g(ACS)¥H¤Î¿}§¿¯f±wªÌ(DM)¡C LEADERS¬ã¨s²¤¶ LEADERS¬ã¨s¬O­º¶µÀH¾÷ª½±µ¤ñ¸û¨âºØ§Q²ö¥q(limus)ÃþÃĪ«¶î¼h¦åºÞ¤ä¬[ªº¬ã¨s¡C¨ä¯SÂI¬OÆ[¹î¦b¯u¹ê¥@¬É¤¤©Ò¦³±µ¨üªvÀøªÌªºÁ{§É®ÄªG¡A¨Ã¯à¯u¥¿¤Ï¬M¥XÁ{§ÉªvÀøª¬ªp¡C¸Ó¬ã¨s¬O¤@¶µ¥Ñ¦h®aÂå¾Ç¤¤¤ß©Ò²Õ¦¨¤§ÀH¾÷¬ã¨s¡A¦@¦³1707¦ì»Ý¶i¦æ«aª¬°Ê¯ß¦¨§Î³NªvÀøªº¯f¤H°Ñ»P¡A¥L­Ì³Q¤À§O´Ó¤J·s¤@¥N¥i§l¦¬³æ­±¶îÃĤßŦ¦åºÞ¤ä¬[©Î¦èù²ö¥q¶Ç²ÎÃĪ«¶î¼h¦åºÞ¤ä¬[¡C¸Ó¬ã¨sªº¯f¤H¿z¿ï¼Ð·Ç¼eÃP¡A¨S¦³­­¨î«aª¬°Ê¯ßÃþ«¬¡B¯f¨_ªø«×¡B¥H¤Î»Ý­nªvÀøªº¯f¨_¼Æ¶q¡A¯u¹ê¤Ï¬M¤F¹ê»ÚÁ{§ÉªvÀø±¡ªp¡CLEADERS¬°´Á¨â¦~ªº¬ã¨sµ²ªG©ó 2009¦~9¤ë¦b¬ü°êª÷¤sÁ|¦æªº²Ä21©¡¸g¾ÉºÞªvÀø¤ßŦ¦åºÞ¾Ç³N¬ã°Q·|¦~·|(TCT 2009)¤Wµoªí¡C¦ÓLEADERS²Ä¤T¦~ªº¬ã¨sµ²ªG©ó2010¦~9¤ë¦b¬ü°êµØ²±¹y¥«Á|¦æªº²Ä22©¡¸g¾ÉºÞªvÀø¤ßŦ¦åºÞ¾Ç³N¬ã°Q·|¦~·|(TCT 2010)¤Wµoªí¡C ¸Ó¾Ç³N¦~·|¥Ñ¬ü°ê¤ß¦åºÞ¬ã¨s°òª÷·|(Cardiovascular Research Foundation)ÃÙ§UÁ|¿ì¡C





   µoªí¥DÃD ¦^ÂÐ¥DÃD

¥Ø«e©|µL¦^ÂÐ...

¤ý®v¤÷±M·~Àð¾À¤Á¤ÕÆp¤Õ¤Þ¤Õ¤uµ{ªA°È
¥x¥_Æp¤Õ¤Á³Î ¤T­«Æp¤Õ¤Á³Î
ªO¾ôÆp¤Õ¤Á³Î ·s²øÆp¤Õ¤Á³Î
Àð¾ÀÆp¤Õ¤Á³Î,Àð­±¤Þ¤ÕÆp¤Õ,¦aªOÆp¤Õ¤Á³Î

[±ÀÂ˵û»ù¦n©±] - 4C§Ö­×³sÂêªù¥« ±M·~ºû­×¶R½æ-µ§¹q+¤â¾÷+¹q¸£+Iphone+Ipad
·s¥_¦Á¤î©± (02) 7751-9182
·s¥_¥«¦Á¤î°ÏºÖ¼w¤@¸ô86«Ñ22¸¹
·s¥_ªO¾ô©± (02) 8257-3990
·s¥_¥«ªO¾ô°Ï¥|ºû¸ô137«Ñ10¸¹
®ç¶é¤j·Ë©± (03) 387-4353
®ç¶é¥«¤j·Ë°Ï¦Z§À«Ñ1-2¸¹
¥x¤¤¥«°Ï©± (04) 2201-1289
¥x¤¤¥«¤¤°Ï¥x¤¤¸ô140¸¹


   ¥xÆWÂåÀø½×¾Â ¦^³»ºÝ
¦Û¾AÀ³ºô­¶½d¥»


³sµ²Àu¨}¸ê°T¤J¤fºô ¥»¯¸¤J³ò½ÃºÖ³¡95¦~«×Àu¨}°·±d¸ê°Tºô¯¸ ¥xÆWÂåÀøºô © 2006 Taiwan Inc. All Rights Reserved.

*«ØÄ³IE5.0¥H¤W¤§ÂsÄý¾¹ ¸ÑªR1024*768 ¥H¹F³Ì¨ÎÂsÄý®ÄªG* ¥þ¯¸¨Ì¤º®e¤À¯Å³W©w³B²z